Abstract

BackgroundHepatitis B is a serious global public health concern. Though a safe and efficacious recombinant vaccine is available, its use in several resource-poor countries is limited by cost. We have investigated the production of Hepatitis B virus surface antigen (HBsAg) using the yeast Pichia pastoris GS115 by inserting the HBsAg gene into the alcohol oxidase 1 locus.ResultsLarge-scale production was optimized by developing a simple fed-batch process leading to enhanced product titers. Cells were first grown rapidly to high-cell density in a batch process using a simple defined medium with low salt and high glycerol concentrations. Induction of recombinant product synthesis was carried out using rather drastic conditions, namely through the addition of methanol to a final concentration of 6 g L-1. This methanol concentration was kept constant for the remainder of the cultivation through continuous methanol feeding based on the on-line signal of a flame ionization detector employed as methanol analyzer in the off-gas stream. Using this robust feeding protocol, maximum concentrations of ~7 grams HBsAg per liter culture broth were obtained. The amount of soluble HBsAg, competent for assembly into characteristic virus-like particles (VLPs), an attribute critical to its immunogenicity and efficacy as a hepatitis B vaccine, reached 2.3 grams per liter of culture broth.ConclusionIn comparison to the highest yields reported so far, our simple cultivation process resulted in an ~7 fold enhancement in total HBsAg production with more than 30% of soluble protein competent for assembly into VLPs. This work opens up the possibility of significantly reducing the cost of vaccine production with implications for expanding hepatitis B vaccination in resource-poor countries.

Highlights

  • Hepatitis B is a serious global public health concern

  • We present a simple fed-batch protocol developed for high-level production of recombinant proteins by P. pastoris and the application of this procedure for the intracellular production of Hepatitis B virus surface antigen (HBsAg)

  • We demonstrate that our simple cultivation process resulted in ~7 fold enhancement in total HBsAg production compared

Read more

Summary

Introduction

Hepatitis B is a serious global public health concern. Though a safe and efficacious recombinant vaccine is available, its use in several resource-poor countries is limited by cost. HBV infection represents a major human disease and is a serious global public health concern [1,2]. This situation still prevails despite the availability of an efficacious hepatitis B vaccine since the early eighties. The advent of a safe recombinant hepatitis B vaccine which has helped to reduce the cost has resulted in the inclusion of hepatitis B vaccination in the national infant immunization schedules of around 160 countries [3]. In many of these countries vaccination coverage is less than 80% and there are several countries in which the vaccine has yet to be introduced

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call